<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01860742</url>
  </required_header>
  <id_info>
    <org_study_id>IJBMNCASTOR</org_study_id>
    <secondary_id>2012-005545-20</secondary_id>
    <nct_id>NCT01860742</nct_id>
  </id_info>
  <brief_title>Randomized Phase III of PRRT Versus Interferon</brief_title>
  <acronym>CASTOR</acronym>
  <official_title>Carcinoid Tumors After Failure of Somatostatin Analogs: a Randomized Phase III of Octreotide Lutate Peptid Receptor Radionuclide Therapy (PRRT) Versus Interferon α-2b</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jules Bordet Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jules Bordet Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the benefit of 177Lu-DOTATATE versus interferon α-2b&#xD;
      in patients with progressive, unresectable, non-pancreatic gastrointestinal neuroendocrine&#xD;
      tumors resistant to therapy with somatostatin analogues, in terms of disease control.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase III study of Peptid Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE&#xD;
      versus Interferon α-2b.&#xD;
&#xD;
      Objectives of the study:&#xD;
&#xD;
        1. To assess the benefit of 177Lu-DOTATATE versus interferon α-2b in patients with&#xD;
           progressive, unresectable,non-pancreatic gastrointestinal neuroendocrine tumors,&#xD;
           resistant to therapy with somatostatin analogues, in terms of disease control.&#xD;
&#xD;
        2. To assess efficacy and safety parameters of both treatment arms and the predictive value&#xD;
           of tumor 68Ga-DOTATATE PET/CT and 18FDG PET/CT uptake at baseline, at mid (+/- 16th&#xD;
           week) and end (+/- 32th week) of treatment in both arms.&#xD;
&#xD;
      In the interferon arm: 5000000 Units of interferon will be administered subcutaneously&#xD;
      preferentially in the evening three times a week (every other day) until disease progression.&#xD;
&#xD;
      In the 177Lu-octreotate arm: Treatment will consist of 177Lu-DOTATATE intravenous injections&#xD;
      fractionated in fixed activities of 7,4 GigaBecquerel (200mCi) (+/- 5%), given every 8 (+/-&#xD;
      1) weeks with simultaneous nephroprotective infusion of an amino acid solution. (Before amino&#xD;
      acid nephroprotection solution, ondansetron, methylprednisolone and metoclopramid, are given&#xD;
      in infusions in order to prevent nausea or vomiting). Approximately 30 min after the&#xD;
      beginning of the aminoacid solution, 177Lu-octreotate is injected via a second side-line over&#xD;
      15-30 minutes. The amino acid infusion is continued at the same rate until end (total&#xD;
      infusion time: 4-6 hours).&#xD;
&#xD;
      In total, 4 injections of 177Lu-DOTATATE are planned. However, in respect of the absorded&#xD;
      dose limits of critical organs(kidneys and bone marrow), the 4th 177Lu-DOTATATE injection&#xD;
      will be tailored with a minimal administered activity of 4,6 GigaBecquerel.&#xD;
&#xD;
      Treatment efficacy will be assessed on a patient-basis using RECIST 1.1 and by Progression&#xD;
      Free Survival. The value of tumor 68Ga-DOTATATE PET/CT and 18FDG PET/CT uptake as predicting&#xD;
      imaging biomarkers will also be assessed in both arms.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">October 2016</completion_date>
  <primary_completion_date type="Anticipated">October 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>3 years [Anticipated]</time_frame>
    <description>PFS is defined by the time between treatment initiation and the first of the following events:&#xD;
Disease progression according to RECIST 1.1;&#xD;
Death of the patient from any cause;&#xD;
Appearance of confirmed new lesion(s) on 68Ga-DOTATATE PET/CT or 18FDG PET/CT.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment response according to RECIST 1.1 (Response Evaluation Criteria In Solid Tumors)</measure>
    <time_frame>3 years [Anticipated]</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events according to Common Terminology Criteria for Adverse Events version 4.03 (CTC 4.03-WHO criteria)</measure>
    <time_frame>3 years [Anticipated]</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor 18FDG PET/CT and 68Ga-octreotate PET/CT uptake at baseline, at mid and end of treatment</measure>
    <time_frame>3 years [Anticipated]</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Gastro-intestinal Neuroendocrine Tumors</condition>
  <arm_group>
    <arm_group_label>Interferon alpha-2b</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Interferon α-2b in a dose of 5000000 Units administered subcutaneously every second day until progression or unacceptable adverse event from a clinical or a patient point of view.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>177Lu-DOTATATE</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>intravenous injection of 177Lu-octreotate with simultaneous infusion of an aminoacid solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interferon alpha-2b</intervention_name>
    <description>Interferon α-2b in a dose of 5000000 Units administered subcutaneously every second day</description>
    <arm_group_label>Interferon alpha-2b</arm_group_label>
    <other_name>Intron A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>177Lu-DOTATATE</intervention_name>
    <description>177Lu-octreotate infusions in fixed activities of 7,4 GigaBecqurel each, given 8-11 weeks apart, injected intravenously with simultaneous infusion of an amino acid solution</description>
    <arm_group_label>177Lu-DOTATATE</arm_group_label>
    <other_name>177Lu-octreotate</other_name>
    <other_name>Lutate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adult patients (≥ 18 yrs).&#xD;
&#xD;
          2. Histology-proven non-pancreatic gastrointestinal NETs.&#xD;
&#xD;
          3. Disease progression under SSAs (SSAs-resistant disease). Disease progression must be&#xD;
             documented with at least one of the following:&#xD;
&#xD;
               -  Radiological disease progression (according to RECIST 1.1) on an MRI or CT over&#xD;
                  the last 12 months.&#xD;
&#xD;
               -  Disease progression on a somatostatin receptor-imaging (PET/CT or SPECT/CT) over&#xD;
                  the last 12 months (apparition of new lesion(s) or increase in the transaxial&#xD;
                  plane diameter of more than 30% on the same imaging modality).&#xD;
&#xD;
          4. There should be at least one target lesion. A target lesion should fulfill all the&#xD;
             following criteria:&#xD;
&#xD;
               -  Uptake higher than the physiological liver uptake on the baseline 68Ga-DOTATATE&#xD;
                  PET/CT&#xD;
&#xD;
               -  Longest transaxial plane diameter ≥ 20mm measured on the CT or MRI;&#xD;
&#xD;
               -  Not previously irradiated.&#xD;
&#xD;
          5. Long-acting SSAs must be discontinued at least 4 weeks before the study treatment&#xD;
             start date and, if needed, switched to short-acting analogues which must be stopped&#xD;
             48h before the treatment date.&#xD;
&#xD;
          6. Adequate renal function with GFR ≥ 50 mL/min/1.73m2 (evaluated by 51Cr-EDTA test).&#xD;
&#xD;
          7. Adequate bone marrow function with:&#xD;
&#xD;
               -  Hemoglobin ≥ 9 g/dL;&#xD;
&#xD;
               -  Neutrophil ≥ 1.5·109/L;&#xD;
&#xD;
               -  Platelet count ≥ 100·109/L.&#xD;
&#xD;
          8. Adequate liver function with:&#xD;
&#xD;
               -  Total Bilirubin ≤ 2xULN;&#xD;
&#xD;
               -  Transaminases (AST and ALT) ≤ 5xULN;&#xD;
&#xD;
               -  Serum albumin &gt; 3.0 g/dL with normal prothrombin time (&gt;70%) unless for patients&#xD;
                  under coumarin anticoagulation therapy.&#xD;
&#xD;
          9. ECOG Performance Status ≤ 1.&#xD;
&#xD;
         10. Women of childbearing potential and men with partners of childbearing potential must&#xD;
             agree to use a highly effective form of contraception for the duration of study&#xD;
             participation and up to six months after the end of the treatment. A pregnancy test&#xD;
             (serum) must be performed within 2 weeks prior to inclusion for every female patient&#xD;
             of childbearing potential and it must be negative.&#xD;
&#xD;
         11. Patient's written informed consent obtained prior to any study specific procedure.&#xD;
&#xD;
         12. All necessary baseline procedures should be performed within 2 weeks prior to&#xD;
             randomization date.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Resectable tumor with curative intent.&#xD;
&#xD;
          2. Any major surgery within the last 6 weeks prior to inclusion in the study.&#xD;
&#xD;
          3. Radiotherapy, chemotherapy, embolization, mammalian target of rapamycin&#xD;
             (mTOR)-inhibitors, receptor tyrosine-kinase inhibitors or other investigational&#xD;
             therapy within 12 weeks prior to inclusion in the study.&#xD;
&#xD;
          4. Previous PRRT or MIBG treatment.&#xD;
&#xD;
          5. Treatment with interferon 12 months prior to inclusion in the study.&#xD;
&#xD;
          6. Presence of non-benign 18FDG-positive lesions (higher than 2 x normal liver (or&#xD;
             thoracic aorta uptake -SUVmax- in case of liver involvement)) without significant&#xD;
             68Ga-DOTATATE uptake.&#xD;
&#xD;
          7. Uncontrolled congestive heart failure (NYHA stade ≥ 2).&#xD;
&#xD;
          8. Diffuse bone marrow infiltration on the baseline 68Ga-DOTATATE PET/CT confirmed by&#xD;
             MRI.&#xD;
&#xD;
          9. Prior external beam radiotherapy on kidneys or on more than 25% of bone marrow.&#xD;
&#xD;
         10. Patients with known uncontrolled brain metastases.&#xD;
&#xD;
         11. History of other active malignant disease or clinical remission less than 5 years&#xD;
             (except in case of non melanoma skin cancer or in situ cervical carcinoma).&#xD;
&#xD;
         12. Known autoimmune hepatitis.&#xD;
&#xD;
         13. Patients after organ transplantation under immunosuppressive therapy.&#xD;
&#xD;
         14. Patients with a significant medical, neuro-psychiatric, or surgical condition,&#xD;
             currently uncontrolled by treatment, which, in the investigator's opinion, may&#xD;
             interfere with completion of the study.&#xD;
&#xD;
         15. Hypersensitivity to interferon α-2b or to any component of the product.&#xD;
&#xD;
         16. Pregnant or lactating patients.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick Flamen, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jules Bordet Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christophe Deroose, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>UZ Leuven</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jules Bordet Institute</name>
      <address>
        <city>Brussels</city>
        <zip>B-1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>B-3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <study_first_submitted>May 21, 2013</study_first_submitted>
  <study_first_submitted_qc>May 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 23, 2013</study_first_posted>
  <last_update_submitted>April 4, 2016</last_update_submitted>
  <last_update_submitted_qc>April 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Peptide Receptor Radionuclide Therapy (PRRT)</keyword>
  <keyword>Neuroendocrine Tumors</keyword>
  <keyword>Interferon alpha</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroendocrine Tumors</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Interferon alpha-2</mesh_term>
    <mesh_term>Lutetium Lu 177 dotatate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

